AIMS/HYPOTHESIS: We studied the relationship between the lipid profile, estimated GFR (eGFR) and AER in patients with type 1 diabetes. We also assessed the association between the lipid profile and glycaemic control, obesity and hypertension in an environment free of manifest renal disease, as well as exploring how well the patients would have achieved the targets set in international guidelines. METHODS: A total of 2,927 adult patients who had type 1 diabetes and for whom lipid profiles were available were included from people participating in the nationwide, multicentre Finnish Diabetic Nephropathy Study (FinnDiane). eGFR was determined using the Cockcroft-Gault formula adjusted for body surface area. RESULTS: Patients with impaired renal function (eGFR <60 ml min(-1) 1.73 m(-2)) had higher total cholesterol, triacylglycerol and apolipoprotein B, and lower HDL-cholesterol concentrations than patients with normal renal function (eGFR >90 ml min(-1) 1.73 m(-2)) or mildly impaired renal function (eGFR 60-90 ml min(-1) 1.73 m(-2)) (p < 0.001 for all associations). In type 1 diabetic patients without manifest renal disease, similar adverse lipid profiles could be observed in those who were overweight or obese and in those who had intermediate or poor glycaemic control or hypertension. In all the different patient groups 14 to 43% would have achieved the recommended target of <2.6 mmol/l for LDL-cholesterol. CONCLUSIONS/ INTERPRETATION: Multiple lipid abnormalities are not only present in type 1 diabetic patients with an abnormal AER, but also in those with impaired renal function. In patients without manifest renal disease, obesity, glycaemic control or hypertension were associated with an adverse lipid profile. A substantial number of patients studied would have exceeded the targets set by international guidelines, particularly the targets for LDL-cholesterol.
AIMS/HYPOTHESIS: We studied the relationship between the lipid profile, estimated GFR (eGFR) and AER in patients with type 1 diabetes. We also assessed the association between the lipid profile and glycaemic control, obesity and hypertension in an environment free of manifest renal disease, as well as exploring how well the patients would have achieved the targets set in international guidelines. METHODS: A total of 2,927 adult patients who had type 1 diabetes and for whom lipid profiles were available were included from people participating in the nationwide, multicentre Finnish Diabetic Nephropathy Study (FinnDiane). eGFR was determined using the Cockcroft-Gault formula adjusted for body surface area. RESULTS:Patients with impaired renal function (eGFR <60 ml min(-1) 1.73 m(-2)) had higher total cholesterol, triacylglycerol and apolipoprotein B, and lower HDL-cholesterol concentrations than patients with normal renal function (eGFR >90 ml min(-1) 1.73 m(-2)) or mildly impaired renal function (eGFR 60-90 ml min(-1) 1.73 m(-2)) (p < 0.001 for all associations). In type 1 diabeticpatients without manifest renal disease, similar adverse lipid profiles could be observed in those who were overweight or obese and in those who had intermediate or poor glycaemic control or hypertension. In all the different patient groups 14 to 43% would have achieved the recommended target of <2.6 mmol/l for LDL-cholesterol. CONCLUSIONS/ INTERPRETATION:Multiple lipid abnormalities are not only present in type 1 diabeticpatients with an abnormal AER, but also in those with impaired renal function. In patients without manifest renal disease, obesity, glycaemic control or hypertension were associated with an adverse lipid profile. A substantial number of patients studied would have exceeded the targets set by international guidelines, particularly the targets for LDL-cholesterol.
Authors: K W Hansen; M Mau Pedersen; C K Christensen; A Schmitz; J S Christiansen; C E Mogensen Journal: J Intern Med Date: 1992-08 Impact factor: 8.989
Authors: M Passarelli; S Catanozi; E R Nakandakare; J C Rocha; R E Morton; A F Shimabukuro; E C Quintão Journal: Diabetologia Date: 1997-09 Impact factor: 10.122
Authors: Wing Yee So; Alice P S Kong; Ronald C W Ma; Risa Ozaki; Cheuk Chun Szeto; Norman N Chan; Vanessa Ng; Chung Shun Ho; Christopher W K Lam; Chun Chung Chow; Clive S Cockram; Juliana C N Chan; Peter C Y Tong Journal: Diabetes Care Date: 2006-09 Impact factor: 19.112
Authors: H C Gerstein; J F Mann; Q Yi; B Zinman; S F Dinneen; B Hoogwerf; J P Hallé; J Young; A Rashkow; C Joyce; S Nawaz; S Yusuf Journal: JAMA Date: 2001-07-25 Impact factor: 56.272
Authors: P H Groop; T Elliott; A Ekstrand; A Franssila-Kallunki; R Friedman; G C Viberti; M R Taskinen Journal: Diabetes Date: 1996-07 Impact factor: 9.461
Authors: Kelli M Sas; Pradeep Kayampilly; Jaeman Byun; Viji Nair; Lucy M Hinder; Junguk Hur; Hongyu Zhang; Chengmao Lin; Nathan R Qi; George Michailidis; Per-Henrik Groop; Robert G Nelson; Manjula Darshi; Kumar Sharma; Jeffrey R Schelling; John R Sedor; Rodica Pop-Busui; Joel M Weinberg; Scott A Soleimanpour; Steven F Abcouwer; Thomas W Gardner; Charles F Burant; Eva L Feldman; Matthias Kretzler; Frank C Brosius; Subramaniam Pennathur Journal: JCI Insight Date: 2016-09-22
Authors: N Tolonen; C Forsblom; L Thorn; J Wadén; M Rosengård-Bärlund; M Saraheimo; M Feodoroff; V-P Mäkinen; D Gordin; M-R Taskinen; P-H Groop Journal: Diabetologia Date: 2009-10-10 Impact factor: 10.122
Authors: Shona J Livingstone; Helen C Looker; Eleanor J Hothersall; Sarah H Wild; Robert S Lindsay; John Chalmers; Stephen Cleland; Graham P Leese; John McKnight; Andrew D Morris; Donald W M Pearson; Norman R Peden; John R Petrie; Sam Philip; Naveed Sattar; Frank Sullivan; Helen M Colhoun Journal: PLoS Med Date: 2012-10-02 Impact factor: 11.069
Authors: Mariann I Lassenius; Kirsi H Pietiläinen; Kati Kaartinen; Pirkko J Pussinen; Jaana Syrjänen; Carol Forsblom; Ilkka Pörsti; Aila Rissanen; Jaakko Kaprio; Jukka Mustonen; Per-Henrik Groop; Markku Lehto Journal: Diabetes Care Date: 2011-06-02 Impact factor: 19.112
Authors: Roberta A Cobas; Bráulio Santos; Pedro Cb da Silva; Ricardo Neves; Marilia B Gomes Journal: Diabetol Metab Syndr Date: 2011-08-26 Impact factor: 3.320
Authors: Marília B Gomes; Roberta A Cobas; Alessandra S Matheus; Lucianne R Tannus; Carlos Antonio Negrato; Melanie Rodacki; Neuza Braga; Marilena M Cordeiro; Jorge L Luescher; Renata S Berardo; Marcia Nery; Maria do Carmo A Arruda-Marques; Luiz E Calliari; Renata M Noronha; Thais D Manna; Lenita Zajdenverg; Roberta Salvodelli; Fernanda G Penha; Milton C Foss; Maria C Foss-Freitas; Antonio C Pires; Fernando C Robles; Mariadefátimas Guedes; Sergio A Dib; Patricia Dualib; Saulo C Silva; Janice Sepulvida; Henriqueta G Almeida; Emerson Sampaio; Rosangela Rea; Ana Cristina R Faria; Balduino Tschiedel; Suzana Lavigne; Gustavo A Cardozo; Mirela J Azevedo; Luis Henrique Canani; Alessandra T Zucatti; Marisa Helena C Coral; Daniela Aline Pereira; Luiz Antonio Araujo; Monica Tolentino; Hermelinda C Pedrosa; Flaviane A Prado; Nelson Rassi; Leticia B Araujo; Reine Marie C Fonseca; Alexis D Guedes; Odelissa S Matos; Manuel Faria; Rossana Azulay; Adriana C Forti; Cristina Façanha; Ana Paula Montenegro; Renan Montenegro; Naira H Melo; Karla F Rezende; Alberto Ramos; João Sooares Felicio; Flavia M Santos; Deborah L Jezini; Marilena M Cordeiro Journal: Diabetol Metab Syndr Date: 2012-10-29 Impact factor: 3.320
Authors: Ville-Petteri Mäkinen; Carol Forsblom; Lena M Thorn; Johan Wadén; Daniel Gordin; Outi Heikkilä; Kustaa Hietala; Laura Kyllönen; Janne Kytö; Milla Rosengård-Bärlund; Markku Saraheimo; Nina Tolonen; Maija Parkkonen; Kimmo Kaski; Mika Ala-Korpela; Per-Henrik Groop Journal: Diabetes Date: 2008-06-10 Impact factor: 9.461
Authors: Gareth J McKay; David A Savage; Christopher C Patterson; Gareth Lewis; Amy Jayne McKnight; Alexander P Maxwell Journal: PLoS One Date: 2013-03-26 Impact factor: 3.240